ALLIANCE-A211601 Evaluation of Mammographic Effect of Aspirin
MD Anderson Study Status
This phase III trial evaluates mammographic breast density in participants with hormone receptor-negative breast cancer enrolled on study A011502. High breast density has been shown to be a strong risk factor for developing breast cancer and decreasing breast density may decrease the risk for breast cancer. Participants treated with aspirin may show reduced breast density on a mammogram.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Breast Carcinoma, Estrogen Receptor Negative, Progesterone Receptor Negative
Breast Surgical Oncology
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.